In January 2021, Combined Therapeutics began working with the Precisions Vaccine Program (PVP) at Boston Children’s Hospital – Harvard Medical School to evaluate our mRNA-based molecular adjuvants in their preclinical vaccine models.
Partner with Us
Combined Therapeutics is currently pursuing licensing and co-development partnerships to bring its proprietary Multi-Organ Protection (MOP) platform to patients worldwide. Our MOP technology is a scalable, modular, and clinically relevant innovation for mRNA applications, ready for out-licensing or collaborative development. With a robust IP portfolio and validated tissue-specific expression, our technology is designed to improve the safety, efficacy, and durability of mRNA-based therapeutics across multiple indications.
CTx has a dominant IP position on the mRNA MOP technology in several countries including the US. With issued U.S. patents, we’re now seeking licensing partners or co-development alliances for prophylactic vaccines, oncology and immunology.
Please fill the form to download our executive summary for infectious diseases applications and oncology applications.
